Genmab — November 2017
-
Der er allerede sikkerhedsdata fra det fase 2 studie, vi talte om tidligere, og som måske kunne danne basis for en ansøgning til 1. linje godkendelse i den del der får transplantation. Der er ikke konstateret nye sikkerhedsproblemer. Studiet har iflg Genmab nu fået navnet Griffin. https://ash.confex.com/ash/2017/webprogram/Paper99989.html
-
In summary, we found daratumumab is a highly effective novel monotherapy for T-ALL in preclinical models. Based on this work, we are planning to open a multi-institutional early phase clinical trial for children and young adults with relapsed and refractory T-ALL.https://ash.confex.com/ash/2017/webprogram/Paper101472.html
-
Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
Abstract # 1495
Saturday, December 9, 5:30 - 7:30 p.m. ET -
today announced that Phase 1 data on flotetuzumab, MacroGenics' CD123 x CD3 bispecific DART
molecule, will be featured in three presentations, including an oral session, at the 59th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta on December 9-12, 2017. -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind